• COVID-19
  • Biosimilars
  • Cataract Therapeutics
  • DME
  • Gene Therapy
  • Workplace
  • Ptosis
  • Optic Relief
  • Imaging
  • Geographic Atrophy
  • AMD
  • Presbyopia
  • Ocular Surface Disease
  • Practice Management
  • Pediatrics
  • Surgery
  • Therapeutics
  • Optometry
  • Retina
  • Cataract
  • Pharmacy
  • IOL
  • Dry Eye
  • Understanding Antibiotic Resistance
  • Refractive
  • Cornea
  • Glaucoma
  • OCT
  • Ocular Allergy
  • Clinical Diagnosis
  • Technology

Miravant results revived: Bausch & Lomb to review potential AMD drug

Article

Santa Barbara, CA-Bausch & Lomb will review results of Miravant Medical Technologies' SnET2 trials with an option to negotiate the exclusive worldwide license to develop and commercialize the drug for the treatment of wet age-related macular degeneration (AMD).

Related Videos
Neda Nikpoor, MD, talks about the Light Adjustable Lens at ASCRS 2024
Elizabeth Yeu, MD, highlights from a corneal case report for a patient undergoing the triple procedure
William F. Wiley, MD, shares some key takeaways from his ASCRS presentation on binocularity and aperture optics.
Related Content
Kiora Pharmaceuticals receives grant to fund novel clinical trial endpoints for inherited retinal diseases

Kiora Pharmaceuticals receives grant to fund novel clinical trial endpoints for inherited retinal diseases

Article
Ehsan Sadri, MD, leads an ophthalmology innovation discussion with Jeffry Weinhuff of Visionary Ventures

(EyePod) From idea to impact: Navigating ophthalmic innovation

Podcast
First patient enrolled in LYNX-2 Phase 3 study

First patient enrolled in LYNX-2 Phase 3 study

Article
EyePod: Modifier Gene Therapy: What is it?

EyePod: Modifier Gene Therapy: What is it?

Podcast
First patient dosed in ViGeneron Phase 1b clinical trial of VG901 for the intravitreal treatment of RP

First patient dosed in ViGeneron Phase 1b clinical trial of VG901 for the intravitreal treatment of RP

Article
Efficacy, safety of switching to latanoprostene bunod 0.024% in patients with OAG and OHT

Efficacy, safety of switching to latanoprostene bunod 0.024% in patients with OAG and OHT

Article
© 2024 MJH Life Sciences

All rights reserved.